MSC-428 (Mercureid immunotherapy nanoparticles)

Leave a review
Claim listing
Bookmark
Share
Report
prev
next

Indicaton

MSC-428 is an immuno-modulating multi-target mixed agonist/antagonist.
Extracellular targets: PD-1, CD19, CD25, CD38
Intracellular target: ZAP-70 kinase

Therapeutic indications

Immunology
Inflammation
Oncology

Type of product

Other
Small molecule

Table

Phase

Marketed
Partnering status

Not partnered
Available in

Ukraine, CIS

You may also be interested in

OligoPhore / SemaPhore Peptide-Based RNA Delivery Platforms

Delivers siRNA, antisense oligonucleotides, mRNA and other mRNA modalities to extrahepatic tissues - demonstrated across various indications in oncology (e.g. PDAC, breast cancer, ovarian cancer, lung cancer, melanoma, ATLL, TME), and inflammatory / autoimmune diseases (e.g. OA, RA, enterocolitis), CV (e.g. atherosclerosis, aortic aneurysm)

Discovery

SOT201 (Immunocytokine, PD-1 x IL-15)

solid tumors

Phase I started

SOT109 (Antibody-Drug Conjugate)

solid tumors, mainly colorectal

Discovery

MSC-428 (Mercureid immunotherapy nanoparticles)

Indicaton

Therapeutic indications

Type of product

Company

Table

You may also be interested in

OligoPhore / SemaPhore Peptide-Based RNA Delivery Platforms

SOT201 (Immunocytokine, PD-1 x IL-15)

SOT109 (Antibody-Drug Conjugate)